Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Colorcon
Merck
Harvard Business School
Baxter

Last Updated: June 27, 2022

Sentynl Theraps Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for SENTYNL THERAPS INC, and what generic alternatives to SENTYNL THERAPS INC drugs are available?

SENTYNL THERAPS INC has three approved drugs.

There is one US patent protecting SENTYNL THERAPS INC drugs.

There are six patent family members on SENTYNL THERAPS INC drugs in ten countries and twelve supplementary protection certificates in four countries.

Summary for Sentynl Theraps Inc
International Patents:6
US Patents:1
Tradenames:3
Ingredients:3
NDAs:3

Drugs and US Patents for Sentynl Theraps Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sentynl Theraps Inc NULIBRY fosdenopterin hydrobromide POWDER;INTRAVENOUS 214018-001 Feb 26, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-006 Jan 7, 2011 DISCN Yes No See Plans and Pricing See Plans and Pricing
Sentynl Theraps Inc LEVORPHANOL TARTRATE levorphanol tartrate TABLET;ORAL 074278-001 Mar 31, 2000 AB RX No Yes See Plans and Pricing See Plans and Pricing
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-002 Jan 7, 2011 DISCN Yes No See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Sentynl Theraps Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-005 Jan 7, 2011 6,761,910 See Plans and Pricing
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-005 Jan 7, 2011 7,910,132 See Plans and Pricing
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-002 Jan 7, 2011 6,759,059 See Plans and Pricing
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-004 Jan 7, 2011 6,761,910 See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for SENTYNL THERAPS INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Sublingual Tablets 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.6 mg and 0.8 mg ➤ Subscribe 2014-06-19

Supplementary Protection Certificates for Sentynl Theraps Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0836511 SPC/GB06/022 United Kingdom See Plans and Pricing PRODUCT NAME: FENTANYL HYDROCHLORIDE; REGISTERED: UK EU/1/05/326/001 20060124
0383579 C960030 Netherlands See Plans and Pricing PRODUCT NAME: REMIFENTANYLUM, DESGEWENST IN DE VORM VAN EEN ZUURADDITIE-ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 20601 - RVG 20603 19961015; 36335.00.00, 36335.01.00, 36335.02.00 19960517
1769785 C300521 Netherlands See Plans and Pricing PRODUCT NAME: FENTANYL; REG NO/DATE: EU/2/11/127/001 20111006
0975367 122011000009 Germany See Plans and Pricing PRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Colorcon
Medtronic
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.